Stock Track | Novavax Soars 17.35% Intraday After Beating Q1 Revenue Estimates on Vaccine Deals Strength

Stock Track

May 07

Novavax's stock soared 17.35% during intraday trading on Wednesday, marking a significant upward movement for the vaccine maker.

The surge followed the company's first-quarter financial results, which showed revenue of $139.5 million, substantially beating analysts' average expectation of $78.3 million. The strength was attributed to upfront and milestone payments from vaccine supply and licensing deals, which helped offset pressure from sagging demand for its COVID-19 shot.

Additionally, Novavax reported a narrower-than-expected quarterly net loss of $0.06 per diluted share, compared to analyst estimates for a loss of $0.23. The company's strategy of licensing out assets and partnering early in development was cited as insulating it from policy uncertainty, while management reiterated cost reduction targets and maintained its 2026 adjusted revenue forecast.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1137138837"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1137138837\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1137138837?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-07 01:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1137138837","market":"hk","top_or_hot":-1,"title":"Stock Track | Novavax Soars 17.35% Intraday After Beating Q1 Revenue Estimates on Vaccine Deals Strength","media":"Stock Track","content":"<p>Novavax's stock soared 17.35% during intraday trading on Wednesday, marking a significant upward movement for the vaccine maker.</p><p>The surge followed the company's first-quarter financial results, which showed revenue of $139.5 million, substantially beating analysts' average expectation of $78.3 million. The strength was attributed to upfront and milestone payments from vaccine supply and licensing deals, which helped offset pressure from sagging demand for its COVID-19 shot.</p><p>Additionally, Novavax reported a narrower-than-expected quarterly net loss of $0.06 per diluted share, compared to analyst estimates for a loss of $0.23. The company's strategy of licensing out assets and partnering early in development was cited as insulating it from policy uncertainty, while management reiterated cost reduction targets and maintained its 2026 adjusted revenue forecast.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Novavax Soars 17.35% Intraday After Beating Q1 Revenue Estimates on Vaccine Deals Strength</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Novavax Soars 17.35% Intraday After Beating Q1 Revenue Estimates on Vaccine Deals Strength\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-07 01:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Novavax's stock soared 17.35% during intraday trading on Wednesday, marking a significant upward movement for the vaccine maker.</p><p>The surge followed the company's first-quarter financial results, which showed revenue of $139.5 million, substantially beating analysts' average expectation of $78.3 million. The strength was attributed to upfront and milestone payments from vaccine supply and licensing deals, which helped offset pressure from sagging demand for its COVID-19 shot.</p><p>Additionally, Novavax reported a narrower-than-expected quarterly net loss of $0.06 per diluted share, compared to analyst estimates for a loss of $0.23. The company's strategy of licensing out assets and partnering early in development was cited as insulating it from policy uncertainty, while management reiterated cost reduction targets and maintained its 2026 adjusted revenue forecast.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVAX","symbol_name":"诺瓦瓦克斯医药","start_time":0,"source_url":"","article_id":"1137138837","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1137138837","pubTimestamp":1778087091,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Novavax's stock soared 17.35% during intraday trading on Wednesday, marking a significant upward movement for the vaccine maker.The surge followed the company's first-quarter financial results, which...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"translate_title":"个股追踪|Novavax盘中大涨17.35%，因疫苗交易强劲，Q1营收超预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVAX":1},"content_text":"Novavax's stock soared 17.35% during intraday trading on Wednesday, marking a significant upward movement for the vaccine maker.The surge followed the company's first-quarter financial results, which showed revenue of $139.5 million, substantially beating analysts' average expectation of $78.3 million. The strength was attributed to upfront and milestone payments from vaccine supply and licensing deals, which helped offset pressure from sagging demand for its COVID-19 shot.Additionally, Novavax reported a narrower-than-expected quarterly net loss of $0.06 per diluted share, compared to analyst estimates for a loss of $0.23. The company's strategy of licensing out assets and partnering early in development was cited as insulating it from policy uncertainty, while management reiterated cost reduction targets and maintained its 2026 adjusted revenue forecast.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}